« Back to Farmacia Journal 5/2016

CLINICAL EFFICACY OF MOMETASONE FUROATE INHALATION THERAPY IN ADULTS WITH POST-UPPER RESPIRATORY TRACT INFECTION COUGH

SHANSHAN FENG¹, GUOWEN ZHAN¹, XIAOYA JING¹, YANYAN CHEN², YOUXIONG YANG^1*, HONGLI WANG¹

Download Full Article PDF

This study was designed to explore the curative effect of mometasone furoate inhalation therapy on adult patients with airway hyper-responsiveness (AHR) cough after having upper respiratory tract infection (URI). There were selected 56 patients who were diagnosed with AHR cough (still having dry cough after treatment of URI). They were randomly divided into treatment group and control group. Through chest radiography and nose endoscopy, the patients with chronic lung disease or perennial rhinitis were excluded. Among the included patients, the treatment group was treated with mometasone furoate inhalation therapy and oral administration of loratadine, while the control group was only treated with loratadine. Follow-up checkups were performed respectively after one-week and two-week treatment. Visual analogue scale (VAS) was used to evaluate the cough degree and cough duration of the patients. In the experimental group, cough duration was 11.60 ± 4.30 days; in the control group, it was 15.00 ± 4.85 days; the difference was statistically significant (p < 0.05). The VAS score of the experimental group was significantly lower than that of the control group (p < 0.05). In the early phase of the disease, the application of mometasone furoate inhalation therapy can shorten the duration of post-URI chronic cough and relieve AHR symptoms.